Congratulations to our client, Feldan Therapeutics Inc., on their recently-announced license agreement

Congratulations to our client, Feldan Therapeutics Inc., on their recently-announced license agreement with South Korea-based GC LabCell, granting GC LabCell rights to use the Feldan Shuttle technology in developing and manufacturing modified Natural Killer cells for immunotherapy. This announcement is just one of many recent positive developments for the innovative Quebec City-based company, including the issuance of broad US patent No. 9982267 protecting a new generation of Feldan Shuttles designed for higher efficiency and improved cell viability.
 
Keep up the excellent work, Feldan!